Editorial: Sclerostin and Wnt Signaling - The pathway to bone strength

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 12, 2005, Pages 6741-6743

  Ott, Susan M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; GENE PRODUCT; GLYCOGEN SYNTHASE KINASE 3; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN; PROTEIN DICKKOPF; SCLEROSTIN; UNCLASSIFIED DRUG; WNT PROTEIN; BONE MORPHOGENETIC PROTEIN; SOST PROTEIN, HUMAN;

APOPTOSIS; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE STRENGTH; CRANIAL NERVE; EDITORIAL; FRAGILITY FRACTURE; GENE EXPRESSION; GENE MUTATION; HUMAN; MISSENSE MUTATION; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSCLEROSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BIOMECHANICS; BONE; GENETIC MARKER; METABOLISM; NOTE; PHYSIOLOGY;

ANIMALS; BIOMECHANICS; BONE AND BONES; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; GENETIC MARKERS; HUMANS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 28744448698     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-2370     Document Type: Editorial

References (23)

1. Johnson ML, Gong G, Kimberling W, Recker SM, Kimmel DB, Recker RB 1997 Linkage of a gene causing high bone mass to human chromosome 11 (11q12-13). Am J Hum Genet 60:1326-1332
2. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR, Johnson ML 2002 A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70:11-19
3. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP 2002 High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513-1521
4. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Juppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML 2001 LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513-523
5. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD, Jr. 2003 The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483-2494
6. Jackson A, Vayssiere B, Garcia T, Newell W, Baron R, Roman-Roman S, Rawadi G 2005 Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells. Bone 36:585-598
7. Yaccoby S, Zhan F, Barlogie B, Shaughnessy JD, 2005. Blocking dkk activity in primary myeloma-bearing SCID-rab mice is associated with increased osteoblast activity and bone formation, and inhibition of tumor growth. Proc American Society for Bone and Mineral Research Meeting, Nashville, TN, 2005, Abstract 1125
8. Oyajobi BO, Gupta A, Flores A, Wideman C, Shipman C, Mundy GR, Garrett IR, Dkk1 modulates osteoclastogenesis and bone resorption: implications for myeloma bone disease. Proc American Society for Bone and Mineral Research Meeting, Nashville, TN, 2005, Abstract 1124
9. Liu P, Zhang Y, Li X, Zheng J, Wu D, Enhancement of bone formation by small molecule compounds that disrupt Dkk-LRP5/6 interaction. Proc American Society for Bone and Mineral Research Meeting, Nashville, TN, 2005, Abstract 1062
10. Rawadi G, Roman-Roman S, Boulukos K, Morvan F, Martin P, Pinho S, Pognonec P, Clément-Lacroix P, Niehrs C, Baron R, Dkk proteins control osteoblast function and bone formation both in vitro and in vivo. Proc American Society for Bone and Mineral Research Meeting, Nashville, TN, 2005, Abstract 1001
11. Hartikka H, Makitie O, Mannikko M, Doria AS, Daneman A, Cole WG, Ala-Kokko L, Sochett EB 2005 Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children. J Bone Miner Res 20:783-789
12. Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Benichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y, Warman ML, De Vernejoul MC, Bollerslev J, Van Hul W 2003 Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 72:763-771
13. Rickels MR, Zhang X, Mumm S, Whyte MP 2005 Oropharyngeal skeletal disease accompanying high bone mass and novel LRP5 mutation. J Bone Miner Res 20:878-885
14. Hamersma H, Gardner J, Beighton P 2003 The natural history of sclerosteosis. Clin Genet 63:192-197
15. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J 2001 Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knotcontaining protein. Am J Hum Genet 68:577-589
16. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery B, Foernzler D, Van Hul W 2002 Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 39:91-97
17. Balemans W, Cleiren E, Siebers U, Horst J, Van Hul W 2005 A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene. Bone 36:943-947
18. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D 2005 Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883-19887
19. Semenov M, Tamai K, He X 2005 SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor. J Biol Chem 280:26770-26775
20. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J 2005 Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842-1844
21. Gardner JC, van Bezooijen RL, Mervis B, Hamdy NAT, Löwik CWGM, Hamersma H, Beighton P, Papapoulos SE 2005 Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab 90:6392-6395
22. Kulkarni NH, Halladay DL, Miles RR, Gilbert LM, Frolik CA, Galvin RJ, Martin TJ, Gillespie MT, Onyia JE 2005 Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem 95:1178-1190
23. Warmington K, Ominsky M, Bolon B, Cattley R, Stephens P, Lawson A, Lightwood D, Perkins V, Kirby H, Moore A, Robinson M, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C, Sclerostin monoclonal antibody treatment of osteoporotic rats completely reverses one year of ovariectomy-induced systemic bone loss. Proc American Society for Bone and Mineral Research Meeting, Nashville, TN, 2005, Abstract 1082